Abstract Number: 665 • 2013 ACR/ARHP Annual Meeting
DNA hypermethylation of Forkhead box protein 3 (FOXP3) locus leads to quantitative defects of regulatory T cells in systemic sclerosis
Background/Purpose: Systemic sclerosis (SSc) is a systemic autoimmune disease of which the etiology and pathogenesis remains complex and poorly understood. Attention has recently been directed…Abstract Number: 666 • 2013 ACR/ARHP Annual Meeting
Involvement Of TCR Vdelta1+ NKT Cells In Systemic Sclerosis: Association With Interstitial Pneumonia
Background/Purpose: Interstitial pneumonia (IP) is one of the critical complications in patients with several autoimmune diseases. However, the exact mechanism of IP remains elusive. Recently,…Abstract Number: 667 • 2013 ACR/ARHP Annual Meeting
IL6 and CCL2 Co-Regulate Fibroblast Dependent Trans-Endothelial Migration Of Mononuclear Cells and Fibrotic Response In Scleroderma
Background/Purpose: IL6 is a key mediator recently implicated in activation of extracellular matrix (ECM) proteins in scleroderma (SSc) fibroblasts. CCL2 is a proinflammatory chemokine that…Abstract Number: 668 • 2013 ACR/ARHP Annual Meeting
Enhanced Expression Of The Cold-Sensing Receptor-TRPM8 In Scleroderma Endothelial Cells and Skin and Endothelial Dysfunction Following TRPM8 Activation
Background/Purpose: Cold exposure induces vasospasm and incites reperfusion injury in SSc. The mechanisms responsible for enhanced cold sensitivity in SSc are poorly understood. Transient receptor…Abstract Number: 669 • 2013 ACR/ARHP Annual Meeting
Up-Regulated Expression Of CXCL5 In Circulating Platelets From Patients With Systemic Sclerosis: A Role In Fibrosis
Background/Purpose: Systemic sclerosis (SSc) is a systemic fibroproliferative disease characterized by concomitant occurrence of microvascular injury and autoantibody production. It has long been suggested that…Abstract Number: 671 • 2013 ACR/ARHP Annual Meeting
Autoantibody Diversity In Scleroderma Patients With Antinucleolar Antibodies and Negative For Three Major Disease-Specific Markers
Background/Purpose: Antinuclear antibodies (ANA) in a nucleolar pattern (antinucleolar antibodies, ANoA) by indirect immunofluorescence technique correlate with several autoantibody specificities and clinical manifestations in scleroderma…Abstract Number: 672 • 2013 ACR/ARHP Annual Meeting
Anti-Th/To Antibodies In Various Systemic Rheumatic Diseases Screened By Anti-Rpp25 ELISA
Background/Purpose: Anti-Th/To antibodies (anti-Th) are one of the specificities that show nucleolar staining in indirect immunofluorescence antinuclear antibody test. Anti-Th is associated with systemic sclerosis…Abstract Number: 674 • 2013 ACR/ARHP Annual Meeting
Systemic Sclerosis Disease Subset Is a Better Predictor Of Long Term Outcome Than Autoantibody Profile
Background/Purpose: Disease subset has been shown to strongly correlate with survival and risk of organ complications in patients with systemic sclerosis (SSc). Nevertheless evidence in…Abstract Number: 675 • 2013 ACR/ARHP Annual Meeting
Impact Of Male Sex On Survival In Systemic Sclerosis
Background/Purpose: Systemic sclerosis (SSc) has a female predominance with a female-to-male ratio of 3:1. Sex differences have been seen in many autoimmune diseases; however, little…Abstract Number: 676 • 2013 ACR/ARHP Annual Meeting
Early Systemic Sclerosis: Marker Autoantibody Positive Patients Have A Faster Pace Of The Disease
Background/Purpose: To investigate whether patients affected with any of the 3 subsets of early systemic sclerosis (SSc) i.e. Raynaud’s Phenomenon (RP) with SSc marker autoantibody…Abstract Number: 678 • 2013 ACR/ARHP Annual Meeting
Quantifying Change In Pulmonary Function As a Prognostic Marker In Systemic Sclerosis-Related Interstitial Lung Disease
Background/Purpose: Interstitial lung disease (ILD) is a leading cause of mortality in systemic sclerosis (SSc) but it is not severe or progressive in all patients.…Abstract Number: 679 • 2013 ACR/ARHP Annual Meeting
Validation Of a Novel Radiographic Scoring System For Calcinosis Affecting The Hands Of Patients With Systemic Sclerosis
Background/Purpose: Calcinosis affects approximately 25% of patients with systemic sclerosis (SSc) and is associated with substantial morbidity. There are currently no validated outcome measures…Abstract Number: 680 • 2013 ACR/ARHP Annual Meeting
Diastolic Dysfunction Amongst Autoantibody Subgroups Of Patients With Diffuse Scleroderma
Background/Purpose: Scleroderma or systemic sclerosis (SSc) is an autoimmune disease characterized by microangiopathy, tissue hypoxia, and fibrosis. At least seven different autoantibodies have been identified…Abstract Number: 682 • 2013 ACR/ARHP Annual Meeting
Effects Of Extracoporeal Shock Wave Therapy To The Digital Ulcers Of Scleroderma:a Pilot Study
Background/Purpose: Vasculopathy, immunological abnormalities and excessive tissue fibrosis are key elements in the pathogenesis of Scleroderma (SSc). In winter, patients often display Raynaud syndrome, which…Abstract Number: 683 • 2013 ACR/ARHP Annual Meeting
HRCT Predictors Of Decline In FVC% predicted—Implications For Cohort Enrichment For Scleroderma Lung Disease (SLD) Trials
Background/Purpose: Moderate-to-severe HRCT-defined lung involvement (total lung involvement or fibrosis) is a predictor of decline in FVC% predicted and mortality in SLD. Various staging systems…